

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

			T	
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/049,783	05/28/2002	Lynn Repsis Fraser	78104.037	6101
75	590 04/17/2003			
Intellectual Property Department Dewitt Ross & Stevens 8000 Excelsior Drive Suite 401			EXAMINER	
			AFREMOVA, VERA	
Madison, WI	53717-1914		ART UNIT	PAPER NUMBER
			1651	7
			DATE MAILED: 04/17/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

## Office Action Summary

Application No. 10/049,783

Applicant(s)

Fraser

Examiner

Vera Afremova

Art Unit 1651



The MAILING DATE of this communication appears on the cover sheet with the correspondence address							
Period for Reply							
THE	ORTENED STATUTORY PERIOD FOR REPLY IS SET MAILING DATE OF THIS COMMUNICATION.						
- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.							
- If NO p - Failure - Any re	period for reply specified above is less than thirty (30) days, a reply within the period for reply is specified above, the maximum statutory period will apply of to reply within the set or extended period for reply will, by statute, cause the ply received by the Office later than three months after the mailing date of the petent term adjustment. See 37 CFR 1.704(b).	and will expire SIX (6) he application to becom	MONTHS fr ne ABANDO	rom the mailing date of this communication. DNED (35 U.S.C. § 133).			
Status							
1) 💢	Responsive to communication(s) filed on Jul 18, 20	002					
2a) 🗌	This action is <b>FINAL</b> . 2b) 💢 This act	tion is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11; 453 O.G. 213.							
Disposi	tion of Claims	•					
4) 💢	Claim(s) <u>1 and 34-87</u>			is/are pending in the application.			
4	a) Of the above, claim(s)			is/are withdrawn from consideration.			
5) 🗆	Claim(s)			is/are allowed.			
6) 🗆	Claim(s)			is/are rejected.			
7) 🗆	Claim(s)		. <u>-</u> .	is/are objected to.			
8) 💢	Claims <u>1 and 34-87</u>	are	subject	to restriction and/or election requirement.			
Applica	tion Papers						
9) The specification is objected to by the Examiner.							
10) ☐ The drawing(s) filed on is/are a) ☐ accepted or b) ☐ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner							
If approved, corrected drawings are required in reply to this Office action.							
12) The oath or declaration is objected to by the Examiner.							
	under 35 U.S.C. §§ 119 and 120						
13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) 🕽	a) 💢 All b) 🗆 Some* c) 🗀 None of:						
	1. Certified copies of the priority documents have been received.						
	2. Certified copies of the priority documents have been received in Application No						
3. \times Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  *See the attached detailed Office action for a list of the certified copies not received.							
14) 🗆		·					
<ul> <li>14) ☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).</li> <li>a) ☐ The translation of the foreign language provisional application has been received.</li> </ul>							
15) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.							
Attachment(s)							
,	tice of References Cited (PTO-892)	4) Interview Sun	nmary (PTC	0-413) Paper No(s)			
2) No	tice of Dreftsperson's Petent Drawing Review (PTO-948)	_		t Application (PTO-152)			
3) 💢 Information Disclosure Statement(s) (PTO-1449) Paper No(s)							

Art Unit: 1651

## **DETAILED ACTION**

Claims 1 and 34-87 are pending [Preliminary amendment, Paper No 3 filed 2/15/2002] and subject to restriction requirement.

## Restriction

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1 and 34-57, drawn to a composition for increasing capacitation of mammalian sperm and/or treating infertility comprising at least two agents selected from calcitonin, angiotensin II and/or modulator of adenosine receptor activity.

Group II, claim(s) 58 -71, drawn to a composition comprising human sperm and at least two agents selected from calcitonin, angiotensin II and/or modulator of adenosine receptor activity.

Group III, claim(s) 72-78, drawn to a method for promoting fertility by administering to a mammal a fertility enhancing amount of at least two agents selected from calcitonin, angiotensin II and/or modulator of adenosine receptor activity.

Art Unit: 1651

Group IV, claim(s) 79-85, drawn to a method for the *in vitro* treatment of mammalian sperm with two agents selected from calcitonin, angiotensin II and/or modulator of adenosine receptor activity.

Group V, claim(s) 86 and 87, drawn to a method for stimulating capacitation of mammalian sperm by administering angiotensin II to sperm or to male mammalian or to female mammalian.

The inventions listed as Groups I-IV do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The instant application contains claims drawn to more than one of permissible combination of invention categories. For example: the Group I and II claims are drawn to two distinct products such as a composition with chemical agents and a composition with human sperm. The Groups III and IV methods are distinct as claimed because they require distinct systems of application such as *in vivo* and *in vitro* environments respectively. The Group V method is distinct from the methods of the Groups III and IV because it requires application of a different composition with one agent.

Further, with respect to the Group I-IV inventions, the "special technical features" or the technical features that define a contribution which each of the claimed inventions, considered as a whole, makes over the prior art, is known in the art. For example: a composition comprising at least two agents such as angiotensin II and modulator of adenosine receptor activity or adenosine

Art Unit: 1651

is disclosed by US 5,698549 as effective in increasing nerve growth factor production (col.17, lines 16-18). Thus, the unity of inventions is broken.

37 CFR1.475. Unity of invention before the International Searching Authority, the International Preliminary Examining Authority and during the national stage.

- (a) An international and a national stage application shall relate to one invention only or to a group of inventions so linked as to form a single general inventive concept ("requirement of unity of invention"). Where a group of inventions is claimed in an application, the requirement of unity of invention shall be fulfilled only when there is a technical relationship among those inventions involving one or more of the same or corresponding special technical features. The expression "special technical features" shall mean those technical features that define a contribution which each of the claimed inventions, considered as a whole, makes over the prior art.
- (b) An international or a national stage application containing claims to different categories of invention will be considered to have unity of invention if the claims are drawn only to one of the following combinations of categories:
- (1) A product and a process specially adapted for the manufacture of said product; or
- (2) A product and a process of use of said product; or
- (3) A product, a process specially adapted for the manufacture of the said product, and a use of the said product; or
- (4) A process and an apparatus or means specifically designed for carrying out the said process; or
- (5) A product, a process specially adapted for the manufacture of the said product, and an apparatus or means specifically designed for carrying out the said process.
- (c) If an application contains claims to more or less than one of the combinations of categories of invention set forth in paragraph (b) of this section, unity of invention might not be present.
- (d) If multiple products, processes of manufacture or uses are claimed, the first invention of the category first mentioned in the claims of the application and the first recited invention of each of the other categories related thereto will be considered as the main invention in the claims, see PCT Article 17(3)(a) and § 1.476(c).
- (e) The determination whether a group of inventions is so linked as to form a single general inventive concept shall be made without regard to whether the inventions are claimed in separate claims or as alternatives within a single claim.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Vera Afremova whose telephone number is (703) 308-9351. The examiner can normally be reached on Monday to Friday from 9:00 to 5:30. If attempts to reach the

Art Unit: 1651

examiner by telephone are unsuccessful, the examiner's supervisor, Michael Wityshyn, can be reached on (703) 308-4743. The fax phone number for this Group is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Vera Afremova

Art Unit 1651

VERA AFREMOVA

April 8, 2003

PATENT EXAMINER

V. Ifn